Orexo AB (FRA:C5G)
€ 1.02 0.035 (3.55%) Market Cap: 38.50 Mil Enterprise Value: 80.00 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 52/100

Q4 2021 Orexo AB Earnings Call Transcript

Jan 27, 2022 / 01:00PM GMT
Release Date Price: €2.41 (-14.25%)
Operator

Hello, and welcome to the Orexo Q4 interim report. (Operator Instructions) Today, I am pleased to present CEO, Nikolaj Sørensen; CFO, Joseph DeFeo; and Robert Ronn, Head of R&D. Please go ahead.

Nikolaj SÃ;rensen;publ;President;CEO
Orexo AB

¸ - ()-&

Thank you very much, and welcome to this fourth quarter interim report presentation. It's clearly been an eventful day on the stock exchange, and I can understand there is some anxiety around Orexo. And having listened to some investors and analysts, I understand some of the concern is around the profitability and our Digital Therapies. So I would put a little extra emphasis on these 2 areas and hopefully create some calm about the situation for the company.

So today, and I'm moving to Page #2. We will go through some highlights for the quarter. I will talk about some of the business updates in U.S. Pharma, a little on the pipeline, but I'm joined by Robert Ronn, who will talk a little bit about our new technology platform amorphOX, our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot